Submission for OMB Review; Understanding the Value of Centralized Services Study (New Collection), 67711-67712 [2021-25946]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 226 / Monday, November 29, 2021 / Notices
device, or any other electronic or
mechanical device designed for similar
purposes is prohibited at ASC Meetings.
James R. Park,
Executive Director.
[FR Doc. 2021–25860 Filed 11–26–21; 8:45 am]
BILLING CODE 6700–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Board on Radiation and
Worker Health (ABRWH),
Subcommittee for Dose
Reconstruction Reviews (SDRR),
National Institute for Occupational
Safety and Health (NIOSH)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
CDC announces the following meeting
for the Subcommittee for Dose
Reconstruction Reviews (SDRR) of the
Advisory Board on Radiation and
Worker Health (ABRWH or the Advisory
Board). This meeting is open to the
public, but without a public comment
period. The public is welcome to submit
written comments in advance of the
meeting, to the contact person below.
Written comments received in advance
of the meeting will be included in the
official record of the meeting. The
public is also welcomed to listen to the
meeting by joining the audio conference
(information below). The audio
conference line has 150 ports for callers.
DATES: The meeting will be held on
January 19, 2022, from 10:30 a.m. to
4:00 p.m., EST.
Written comments must be received
on or before January 12, 2022.
ADDRESSES: You may submit comments
by mail to: Sherri Diana, National
Institute for Occupational Safety and
Health, 1090 Tusculum Avenue, MS C–
34, Cincinnati, Ohio 45226. Meeting
Information: Audio Conference Call via
FTS Conferencing. The USA toll-free
dial-in number is 1–866–659–0537; the
pass code is 9933701.
FOR FURTHER INFORMATION CONTACT:
Rashaun Roberts, Ph.D., Designated
Federal Officer, NIOSH, CDC, 1090
Tusculum Avenue, Mailstop C–24,
Cincinnati, Ohio 45226, Telephone:
(513) 533–6800; Toll Free 1(800) CDC–
INFO; Email: ocas@cdc.gov.
SUPPLEMENTARY INFORMATION:
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:55 Nov 26, 2021
Jkt 256001
Background: The Advisory Board was
established under the Energy Employees
Occupational Illness Compensation
Program Act of 2000 to advise the
President on a variety of policy and
technical functions required to
implement and effectively manage the
new compensation program. Key
functions of the Advisory Board include
providing advice on the development of
probability of causation guidelines that
have been promulgated by the
Department of Health and Human
Services (HHS) as a final rule; advice on
methods of dose reconstruction, which
have also been promulgated by HHS as
a final rule; advice on the scientific
validity and quality of dose estimation
and reconstruction efforts being
performed for purposes of the
compensation program; and advice on
petitions to add classes of workers to the
Special Exposure Cohort (SEC). In
December 2000, the President delegated
responsibility for funding, staffing, and
operating the Advisory Board to HHS,
which subsequently delegated this
authority to CDC. NIOSH implements
this responsibility for CDC.
The Advisory Board’s charter was
issued on August 3, 2001, renewed at
appropriate intervals, and rechartered
under Executive Order 13889 on March
22, 2020, and will terminate on March
22, 2022.
Purpose: The Advisory Board is
charged with (a) providing advice to the
Secretary, HHS, on the development of
guidelines under Executive Order
13179; (b) providing advice to the
Secretary, HHS, on the scientific
validity and quality of dose
reconstruction efforts performed for this
program; and (c) upon request by the
Secretary, HHS, advise the Secretary on
whether there is a class of employees at
any Department of Energy facility who
were exposed to radiation but for whom
it is not feasible to estimate their
radiation dose, and on whether there is
reasonable likelihood that such
radiation doses may have endangered
the health of members of this class.
SDRR was established to aid the
Advisory Board in carrying out its duty
to advise the Secretary, HHS, on dose
reconstruction.
Matters to be Considered: The agenda
will include discussions on the
following dose reconstruction program
quality management and assurance
activities: Dose reconstruction cases
under review from Sets 29 and 30,
possibly including cases involving:
Nevada test Site, Oak Ridge Institute for
Science Education, Rocky Flats Plant,
Idaho National Laboratory, Y–12 Plant,
Clarksville Modification Center, Pantex
Plant, Oak Ridge National Laboratory
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
67711
(X–10), Albuquerque Operations Office,
General Atomics, Area IV of the Santa
Susanna Field Laboratory, Oak Ridge
Gaseous Diffusion Plant (K–25),
Savannah River Site (SRS), Hanford,
SRS, X–10, Y–12 Plant, and General
Steel Industries. Agenda items are
subject to change as priorities dictate.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–25863 Filed 11–26–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Submission for OMB Review;
Understanding the Value of Centralized
Services Study (New Collection)
Office of Planning, Research,
and Evaluation, Administration for
Children and Families, HHS.
ACTION: Request for public comment.
AGENCY:
The Administration for
Children and Families (ACF), U.S.
Department of Health and Human
Services (HHS) is proposing a new data
collection activity as part of the
Understanding the Value of Centralized
Services study. The objective of this
descriptive study is to understand the
advantages, disadvantages, and costs of
centralizing services for individuals and
families with low incomes.
DATES: Comments due within 30 days of
publication. OMB must make a decision
about the collection of information
between 30 and 60 days after
publication of this document in the
Federal Register. Therefore, a comment
is best assured of having its full effect
if OMB receives it within 30 days of
publication.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
SUMMARY:
E:\FR\FM\29NON1.SGM
29NON1
67712
Federal Register / Vol. 86, No. 226 / Monday, November 29, 2021 / Notices
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
SUPPLEMENTARY INFORMATION:
Description: This descriptive study
aims to provide insight into the models
that have been used to centralize
services; organizations’ history of and
impetus for centralizing services; the
benefits, challenges, and costs of
centralizing services from the
perspectives of staff and clients; and
how organizations have coordinated
their centralized services virtually. This
project will include site visits to three
centralized community resource centers
(CCRCs). The proposed information
collection activities include interviews
with staff, including leadership and
administrative staff, frontline staff,
finance staff, and IT/data staff, and
focus groups with clients. The research
team will also conduct observations of
program activities.
Respondents: Respondents will
include leadership and administrative
staff at the CCRC, staff who manage
finances at the CCRC, staff who manage
data and/or technology at the CCRC,
staff who provide services directly to
clients at the CCRC, and clients who
have accessed services at the CCRC.
ANNUAL BURDEN ESTIMATES
Number of
respondents
(total over
request
period)
Instrument
Interview guide for administrative/leadership staff ..........................................
Interview guide for frontline staff .....................................................................
Interview guide for finance staff ......................................................................
Interview guide for IT/data staff .......................................................................
Focus group guide for clients ..........................................................................
Estimated Total Annual Burden
Hours: 146.
Authority: Authorized by the Social
Security Act 1110 [42 U.S.C. 1310],
appropriated by the Continuing
Appropriations Act of 2019.
John M. Sweet Jr.,
ACF/OPRE Certifying Officer.
[FR Doc. 2021–25946 Filed 11–26–21; 8:45 am]
BILLING CODE 4184–07–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusivity Under
Non-Exclusive Patent License: AAV
Isolate and Fusion Protein Comprising
Nerve Growth Factor Signal Peptide
and Parathyroid Hormone
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Institute of
Diabetes and Digestive and Kidney
Disease and National Institute of Dental
and Craniofacial Research, institutes of
the National Institutes of Health,
Department of Health and Human
Services, are contemplating the grant of
an exclusive rights under active Nonexclusive Patent License to practice the
inventions embodied in the United
States, European and Japan
Applications listed in the
Supplementary Information section of
this notice to Atsena Therapeutics, Inc.,
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:55 Nov 26, 2021
Jkt 256001
18
48
9
9
30
located in Durham, North Carolina,
USA.
DATES: Only written comments and/or
applications for a license which are
received by the National Institute of
Diabetes and Digestive and Kidney
Disease’s Technology Advancement
Office on or before December 14, 2021
will be considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Vladimir Knezevic, MD,
(Senior) Advisor for Commercial
Evaluation, Technology Advancement
Office, Building 12A, Room 3011,
Bethesda, MD 20817–5632 (for business
mail), Telephone: (301) 435–5560;
Email: vlado.knezevic@nih.gov.
SUPPLEMENTARY INFORMATION:
Intellectual Property
I. European Patent National Stage:
EP3294894 granted 2019–08–14, entitled
‘‘AAV isolate and fusion protein comprising
nerve growth factor signal peptide and
parathyroid hormone’’ (HHS Reference
Number E–175–2015–1–EP–03), validated in
Great Britain, France and Germany.
II. Japanese Application No. 2017–558710
granted 2020–12–20, entitled ‘‘AAV isolate
and fusion protein comprising nerve growth
factor signal peptide and parathyroid
hormone’’ (HHS Reference Number E–175–
2015–1–JP–04).
III. U.S. Patent Application No. 15/573,214
filed 2017–11–10, entitled ‘‘AAV isolate and
fusion protein comprising nerve growth
factor signal peptide and parathyroid
hormone’’ (HHS Reference Number E–175–
2015–1–US–05).
IV. Canadian Patent Application No.
2,985,786 filed 2017–11–10, entitled ‘‘AAV
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
(total over
request
period)
1
1
1
1
1
Avg.
burden per
response
(in hours)
1.25
1.25
1
1
1.5
Total/annual
burden
(in hours)
23
60
9
9
45
isolate and fusion protein comprising nerve
growth factor signal peptide and parathyroid
hormone’’ (HHS Reference Number E–175–
2015–1–CA–02).
The patent rights in these inventions
have been assigned or exclusively
licensed to the Government of the
United States of America.
The prospective exclusive license
territory may be worldwide and in fields
of use that may be limited to treatment
of limited number of monogenic
inherited retinal diseases that affect the
photoreceptors and/or retinal pigmented
epithelium.
The above-listed patent portfolio
covers inventions directed to gene
therapy and specifically, expression
vectors and therapeutic methods of
using such vectors.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing. The prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Institute of Diabetes and Digestive and
Kidney Disease receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially and may be made
publicly available.
License applications submitted in
response to this notice will be presumed
E:\FR\FM\29NON1.SGM
29NON1
]]>Agencies
[Federal Register Volume 86, Number 226 (Monday, November 29, 2021)]
[Notices]
[Pages 67711-67712]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-25946]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Administration for Children and Families
Submission for OMB Review; Understanding the Value of Centralized
Services Study (New Collection)
AGENCY: Office of Planning, Research, and Evaluation, Administration
for Children and Families, HHS.
ACTION: Request for public comment.
-----------------------------------------------------------------------
SUMMARY: The Administration for Children and Families (ACF), U.S.
Department of Health and Human Services (HHS) is proposing a new data
collection activity as part of the Understanding the Value of
Centralized Services study. The objective of this descriptive study is
to understand the advantages, disadvantages, and costs of centralizing
services for individuals and families with low incomes.
DATES: Comments due within 30 days of publication. OMB must make a
decision about the collection of information between 30 and 60 days
after publication of this document in the Federal Register. Therefore,
a comment is best assured of having its full effect if OMB receives it
within 30 days of publication.
ADDRESSES: Written comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting
[[Page 67712]]
``Currently under 30-day Review--Open for Public Comments'' or by using
the search function.
SUPPLEMENTARY INFORMATION:
Description: This descriptive study aims to provide insight into
the models that have been used to centralize services; organizations'
history of and impetus for centralizing services; the benefits,
challenges, and costs of centralizing services from the perspectives of
staff and clients; and how organizations have coordinated their
centralized services virtually. This project will include site visits
to three centralized community resource centers (CCRCs). The proposed
information collection activities include interviews with staff,
including leadership and administrative staff, frontline staff, finance
staff, and IT/data staff, and focus groups with clients. The research
team will also conduct observations of program activities.
Respondents: Respondents will include leadership and administrative
staff at the CCRC, staff who manage finances at the CCRC, staff who
manage data and/or technology at the CCRC, staff who provide services
directly to clients at the CCRC, and clients who have accessed services
at the CCRC.
Annual Burden Estimates
----------------------------------------------------------------------------------------------------------------
Number of
Number of responses per
respondents respondent Avg. burden Total/annual
Instrument (total over (total over per response burden (in
request request (in hours) hours)
period) period)
----------------------------------------------------------------------------------------------------------------
Interview guide for administrative/leadership 18 1 1.25 23
staff..........................................
Interview guide for frontline staff............. 48 1 1.25 60
Interview guide for finance staff............... 9 1 1 9
Interview guide for IT/data staff............... 9 1 1 9
Focus group guide for clients................... 30 1 1.5 45
----------------------------------------------------------------------------------------------------------------
Estimated Total Annual Burden Hours: 146.
Authority: Authorized by the Social Security Act 1110 [42 U.S.C.
1310], appropriated by the Continuing Appropriations Act of 2019.
John M. Sweet Jr.,
ACF/OPRE Certifying Officer.
[FR Doc. 2021-25946 Filed 11-26-21; 8:45 am]
BILLING CODE 4184-07-P
